Top

Published in:

01-03-2022 | Antiepileptic Drugs | Original Article

Perceived quality of life (QOLIE-31-P), depression (NDDI-E), anxiety (GAD-7), and insomnia in patients with epilepsy attended at a refractory epilepsy unit in real-life clinical practice

Authors: Alicia Gonzalez-Martinez, Álvaro Planchuelo-Gómez, Alba Vieira Campos, Francisco Martínez-Dubarbie, José Vivancos, María De Toledo-Heras

Published in: Neurological Sciences | Issue 3/2022

Abstract

Objectives

This study aims to evaluate the relationship between psychiatric comorbidity (anxiety and depression), somnolence, and quality of life, using validated scales in patients with epilepsy in real-life clinical practice and clinical and demographic variables.

Methods

A cross-sectional observational study was conducted. Self-administered scales of anxiety disorders (GAD-7), depression (NDDI-E), somnolence (Epworth Sleepiness Scale (ESS)), and quality of life (QOLIE-31-P) in patients with epilepsy treated in the refractory epilepsy unit of a tertiary hospital were employed.

Results

Eighty-four patients, 44.3 ± 17.4 years, 48.2% women, epilepsy duration 21.5 ± 15.9 years, and number of antiepileptic drugs 1.9 ± 1.2 were included. Severe anxiety was present in 14.3%, depression in 20.2%, and somnolence in 14.3% of patients. QOLIE-31-P score was 62.0 ± 19.2. Depression and focal epilepsy (OR = 4.5[1.3, 20.7], p = 0.029), as well as anxiety and temporal lobe epilepsy (OR = 4.3 [1.0, 18.1], p = 0.044), were associated. Moreover, relationships between worse quality of life and higher scores from NDDI-E (β = − 1.42, adjusted p = 0.006) and GAD-7 (β = − 1.21, adjusted p = 0.006), especially in drug-resistant epilepsy (β = − 8.08, adjusted p = 0.045) and female sex (β = − 7.83, adjusted p = 0.034), were identified. Statistically significant negative associations were observed between problems to fall asleep and overall quality of life score (β = − 11.64, adjusted p = 0.022), sleep disturbance and energy (β = − 14.78, adjusted p = 0.027), and mood (β = 12.40, adjusted p = 0.027) scores.

Conclusions

The multidimensional evaluation revealed that higher levels of anxiety and depression are associated with worse quality of life in real clinical practice in patients with epilepsy, especially in females and drug-resistant epilepsy. In addition, sleep disturbances are associated with particular aspects of the quality of life. Further studies with longitudinal follow-up would be useful to adequately manage these comorbidities in patients with epilepsy.

Available only for authorised users

Bell GS, Sander JW (2001) The epidemiology of epilepsy: the size of the problem. Seizure 10:306–316. https://doi.org/10.1053/seiz.2001.0584CrossRefPubMed

Schachter SC (2006) Quality of life for patients with epilepsy is determined by more than seizure control: the role of psychosocial factors. Expert Rev Neurother 6:111–118. https://doi.org/10.1586/14737175.6.1.111CrossRefPubMed

Schipper H (1983) Why measure quality of life? Can Med Assoc J 128:1367–1370PubMedPubMedCentral

Gutter T, Callenbach PMC, Brouwer OF, de Weerd AW (2019) Prevalence of sleep disturbances in people with epilepsy and the impact on quality of life: a survey in secondary care. Seizure 69:298–303. https://doi.org/10.1016/j.seizure.2019.04.019CrossRefPubMed

Josephson CB, Jetté N (2017) Psychiatric comorbidities in epilepsy. Int Rev Psychiatry 29:409–424. https://doi.org/10.1080/09540261.2017.1302412CrossRefPubMed

Baranowski CJ (2018) The quality of life of older adults with epilepsy: a systematic review. Seizure Eur J Epilepsy 60:190–197. https://doi.org/10.1016/j.seizure.2018.06.002CrossRef

Scott AJ, Sharpe L, Hunt C, Gandy M (2017) Anxiety and depressive disorders in people with epilepsy: a meta-analysis. Epilepsia 58:973–982. https://doi.org/10.1111/epi.13769CrossRefPubMed

de Araújo Filho GM, Martins DP, Lopes AM, de Jesus BB, Furlan AER, Oliveira CIF et al (2018) Oxidative stress in patients with refractory temporal lobe epilepsy and mesial temporal sclerosis: possible association with major depressive disorder? Epilepsy Behav 80:191–196. https://doi.org/10.1016/j.yebeh.2017.12.025CrossRefPubMed

Munger Clary HM, Snively BM, Hamberger MJ (2018) Anxiety is common and independently associated with clinical features of epilepsy. Epilepsy Behav 85:64–71. https://doi.org/10.1016/j.yebeh.2018.05.024CrossRefPubMedPubMedCentral

10.

Kataria L, Vaughn BV (2016) Sleep and epilepsy. Sleep Med Clin 11:25–38. https://doi.org/10.1016/j.jsmc.2015.10.008CrossRefPubMed

11.

Çilliler AE, Güven B (2020) Sleep quality and related clinical features in patients with epilepsy: a preliminary report. Epilepsy Behav 102. https://doi.org/10.1016/j.yebeh.2019.106661

12.

Lin Z, Si Q, Xiaoyi Z (2017) Obstructive sleep apnoea in patients with epilepsy: a meta-analysis. Sleep Breath 21:263–270. https://doi.org/10.1007/s11325-016-1391-3CrossRefPubMed

13.

Kwan P, Arzimanoglou A, Berg AT, Brodie MJ, Allen Hauser W, Mathern G et al (2010) Definition of drug resistant epilepsy: consensus proposal by the ad hoc task force of the ILAE Commission on Therapeutic Strategies. Epilepsia 51:1069–1077. https://doi.org/10.1111/j.1528-1167.2009.02397.xCrossRefPubMed

14.

Cramer JA, Van Hammée G (2003) Maintenance of improvement in health-related quality of life during long-term treatment with levetiracetam. Epilepsy Behav 4:118–123. https://doi.org/10.1016/s1525-5050(03)00004-0CrossRefPubMed

15.

Spitzer RL, Kroenke K, Williams JBW, Löwe B (2006) A brief measure for assessing generalized anxiety disorder: the GAD-7. Arch Intern Med 166:1092–1097. https://doi.org/10.1001/archinte.166.10.1092CrossRefPubMed

16.

García-Campayo J, Zamorano E, Ruiz MA, Pardo A, Pérez-Páramo M, López-Gómez V et al (2010) Cultural adaptation into Spanish of the generalized anxiety disorder-7 (GAD-7) scale as a screening tool. Heal Qual Life Outcomes 8:8. https://doi.org/10.1186/1477-7525-8-8CrossRef

17.

Friedman DE, Kung DH, Laowattana S, Kass JS, Hrachovy RA, Levin HS (2009) Identifying depression in epilepsy in a busy clinical setting is enhanced with systematic screening. Seizure 18:429–433. https://doi.org/10.1016/j.seizure.2009.03.001CrossRefPubMed

18.

Di Capua D, Garcia-Garcia ME, Reig-Ferrer A, Fuentes-Ferrer M, Toledano R, Gil-Nagel A et al (2012) Validation of the Spanish version of the Neurological Disorders Depression Inventory for Epilepsy (NDDI-E). Epilepsy Behav 24:493–496. https://doi.org/10.1016/j.yebeh.2012.06.005CrossRefPubMed

19.

Johns MW (1991) A new method for measuring daytime sleepiness: the Epworth Sleepiness Scale. Sleep 14:540–545. https://doi.org/10.1093/sleep/14.6.540CrossRefPubMed

20.

Chiner E, Arriero JM, Signes-Costa J, Marco J, Fuentes I (1999) Validation of the Spanish version of the Epworth Sleepiness Scale in patients with sleep apnea syndrome. Arch Bronconeumol 35:422–427. https://doi.org/10.1016/S0300-2896(15)30037-5CrossRefPubMed

21.

Scheffer IE, Berkovic S, Capovilla G, Connolly MB, French J, Guilhoto L, Hirsch E, Jain S, Mathern GW, Moshé SL, Nordli DR, Perucca E, Tomson T, Wiebe S, Zhang YH, Zuberi SM (2017) ILAE classification of the epilepsies: position paper of the ILAE Commission for Classification and Terminology. Epilepsia 58(4):512–521. https://doi.org/10.1111/epi.13709CrossRefPubMedPubMedCentral

22.

Micoulaud-Franchi J-A, Bartolomei F, Duncan R, McGonigal A (2017) Evaluating quality of life in epilepsy: the role of screening for adverse drug effects, depression, and anxiety. Epilepsy Behav 75:18–24. https://doi.org/10.1016/j.yebeh.2017.07.016CrossRefPubMed

23.

Tombini M, Assenza G, Quintiliani L, Ricci L, Lanzone J, Ulivi M, Di Lazzaro V (2020) Depressive symptoms and difficulties in emotion regulation in adult patients with epilepsy: association with quality of life and stigma. Epilepsy Behav 107:107073. https://doi.org/10.1016/j.yebeh.2020.107073CrossRefPubMed

24.

Tombini M, Assenza G, Quintiliani L, Ricci L, Lanzone J, De Mojà R, Ulivi M, Di Lazzaro V (2019) Epilepsy-associated stigma from the perspective of people with epilepsy and the community in Italy. Epilepsy Behav 98(Pt A):66–72. https://doi.org/10.1016/j.yebeh.2019.06.026CrossRefPubMed

25.

Baker GA, Jacoby A, Buck D, Stalgis C, Monnet D (1997) Quality of life of people with epilepsy: a European study. Epilepsia 38:353–362. https://doi.org/10.1111/j.1528-1157.1997.tb01128.xCrossRefPubMed

26.

Sander JW, Shorvon SD (1996) Epidemiology of the epilepsies. J Neurol Neurosurg Psychiatry 61:433–443. https://doi.org/10.1136/jnnp.61.5.433CrossRefPubMedPubMedCentral

27.

Laccheo I, Ablah E, Heinrichs R, Sadler T, Baade L, Liow K (2008) Assessment of quality of life among the elderly with epilepsy. Epilepsy Behav 12:257–261. https://doi.org/10.1016/j.yebeh.2007.09.003CrossRefPubMed

28.

Kirmani BF, Robinson DM, Kikam A, Fonkem E, Cruz D (2014) Selection of antiepileptic drugs in older people. Curr Treat Options Neurol 16:295. https://doi.org/10.1007/s11940-014-0295-4CrossRefPubMed

29.

Quiske A, Helmstaedter C, Lux S, Elger CE (2000) Depression in patients with temporal lobe epilepsy is related to mesial temporal sclerosis. Epilepsy Res 39(2):121–125. https://doi.org/10.1016/s0920-1211(99)00117-5CrossRefPubMed

30.

Perini GI, Tosin C, Carraro C, Bernasconi G, Canevini MP, Canger R, Pellegrini A, Testa G (1996) Interictal mood and personality disorders in temporal lobe epilepsy and juvenile myoclonic epilepsy. J Neurol Neurosurg Psychiatry 61(6):601–605. https://doi.org/10.1136/jnnp.61.6.601CrossRefPubMedPubMedCentral

31.

Chen YY, Huang S, Wu WY, Liu CR, Yang XY, Zhao HT, Wu LC, Tan LZ, Long LL, Xiao B (2018) Associated and predictive factors of quality of life in patients with temporal lobe epilepsy. Epilepsy Behav 86:85–90. https://doi.org/10.1016/j.yebeh.2018.06.025CrossRefPubMed

32.

Rocamora R, Ley M, Molins A, Toledo M, Sansa G, Bertol V, Becerra JL, Carreño M, Mauri JÁ (2018) Effect of lacosamide on depression and anxiety symptoms in patients with focal refractory epilepsy: a prospective multicenter study. Epilepsy Behav 79:87–92. https://doi.org/10.1016/j.yebeh.2017.10.032CrossRefPubMed

33.

Moseley BD, Cole D, Iwuora O, Strawn JR, Privitera M (2015) The effects of lacosamide on depression and anxiety in patients with epilepsy. Epilepsy Res 110:115–118. https://doi.org/10.1016/j.eplepsyres.2014.12.007CrossRefPubMed

34.

Alfaro A, Asensio M, García-Escrivá A, Medrano V, Salom JM, Tortosa D, Palao S, Lezcano M, Berenguer L, Navarro M, Cerdán M, Buendía JF, Giner JC (2019) LAM study: effects of lacosamide on behaviour and quality of life in patients with epilepsy. Neurologia 34(1):1–6. English, Spanish. https://doi.org/10.1016/j.nrl.2016.10.007CrossRefPubMed

35.

Zimmermann C, Köhler D, Schönhofer B (2000) Wertigkeit der retrospektiven Einschätzung der Epworth-Schläfrigkeitsskala nach länger dauernder CPAP-Therapie bei obstruktiver, schlafbezogener Atmungsstörung [Value of retrospective assessment of the Epworth Sleepiness Scale after long-term CPAP therapy. Pneumologie 54:572–4. https://doi.org/10.1055/s-2000-9193CrossRefPubMed

36.

Bala A, Szantroch M, Gleinert A, Rysz A, Marchel A (2016) Differences in quality of life of women and men with drug-resistant epilepsy in Poland. Epilepsy Behav 60:94–8. https://doi.org/10.1016/j.yebeh.2016.04.041CrossRefPubMed

37.

Stephen LJ, Harden C, Tomson T, Brodie MJ (2019) Management of epilepsy in women. Lancet Neurol 18:481–91. https://doi.org/10.1016/S1474-4422(18)30495-2CrossRefPubMed

38.

Santos AMC, Castro-Lima H, Matos MAA, Brito MB (2018) Quality of life among women with epilepsy during their reproductive years. Epilepsy Behav 85:10–3. https://doi.org/10.1016/j.yebeh.2018.04.028CrossRefPubMed

39.

Ophey A, Eggers C, Dano R, Timmermann L, Kalbe E (2018) Health-related quality of life subdomains in patients with Parkinson’s disease: the role of gender. Parkinsons Dis 1(2018):6532320. https://doi.org/10.1155/2018/6532320CrossRef

40.

Siarava E, Hyphantis T, Katsanos AH, Pelidou S-H, Kyritsis AP, Markoula S (2019) Depression and quality of life in patients with epilepsy in Northwest Greece. Seizure 66:93–98. https://doi.org/10.1016/j.seizure.2019.02.012CrossRefPubMed

Title: Perceived quality of life (QOLIE-31-P), depression (NDDI-E), anxiety (GAD-7), and insomnia in patients with epilepsy attended at a refractory epilepsy unit in real-life clinical practice
Authors: Alicia Gonzalez-Martinez
Álvaro Planchuelo-Gómez
Alba Vieira Campos
Francisco Martínez-Dubarbie
José Vivancos
María De Toledo-Heras
Publication date: 01-03-2022
Publisher: Springer International Publishing
Keywords: Antiepileptic Drugs
Affective Disorder
Affective Disorder
Epilepsy
Anxiety
Antiepileptic Drugs
Published in: Neurological Sciences / Issue 3/2022
Print ISSN: 1590-1874
Electronic ISSN: 1590-3478
DOI: https://doi.org/10.1007/s10072-021-05595-3

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Perceived quality of life (QOLIE-31-P), depression (NDDI-E), anxiety (GAD-7), and insomnia in patients with epilepsy attended at a refractory epilepsy unit in real-life clinical practice

Abstract

Objectives

Methods

Results

Conclusions

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Objectives

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 3/2022

A p.Glu420Gln mutation in SPAST is associated with infantile onset spastic paraplegia complicated by cerebella ataxia, epilepsy, peripheral neuropathy, and hypoplasia of the corpus callosum

Ulnar neuropathy from accessory epitrochlearis anconeus muscle

Correction to: Sleep duration and efficiency are associated with plasma amyloid-β in non-demented older people

Serum levels of lipocalin-2 in patients with Parkinson’s disease

HSV encephalitis associated with off-label rituximab treatment of multiple sclerosis

Arterial intracranial thrombosis as the first manifestation of vaccine-induced immune thrombotic thrombocytopenia (VITT): a case report